By: J.S., STA
The group around the drug maker Krka generated EUR 1.16 billion in sales revenue in the first nine months of the year, which is 6% more than in the same period last year.
Net profit was up by 22% to EUR 210.14 million. Sales were up the most in Eastern Europe, where the most revenue was generated. Operating profit jumped by 57% to EUR 300.75 million and EBITDA increased by 40% to EUR 384.6 million. Sales were up compared to the same period last year in all regional markets, except Turkmenistan, but the crucial growth was that in Russia, Krka’s largest individual market.